Adaptive Biotechnologies Announces Over 65 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 66th ASH Annual Meeting
Adaptive Biotechnologies (Nasdaq: ADPT) announced that its clonoSEQ® test for measurable residual disease (MRD) assessment will be featured in over 65 abstracts at the 66th ASH Annual Meeting. The presentations span eight different types of blood cancer and include a plenary session, a late-breaking abstract, and 25 oral presentations. The studies demonstrate clonoSEQ's role as a standard for efficacy measurement in pivotal clinical trials and highlight its advantages in both clinical trials and real-world practice. Several practice-changing studies use MRD as a primary endpoint in multiple myeloma, mantle cell lymphoma, and chronic lymphocytic leukemia.
Adaptive Biotechnologies (Nasdaq: ADPT) ha annunciato che il suo test clonoSEQ® per la valutazione della malattia residua misurabile (MRD) sarà presentato in oltre 65 abstract al 66° Congresso Annuale dell'ASH. Le presentazioni riguardano otto diversi tipi di cancro del sangue e includono una sessione plenaria, un abstract a colpo d'occhio e 25 presentazioni orali. Gli studi dimostrano il ruolo di clonoSEQ come standard per la misurazione dell'efficacia nei trial clinici pivotal e mettono in evidenza i suoi vantaggi sia nei trial clinici che nella pratica reale. Diversi studi che cambiano la pratica utilizzano l'MRD come endpoint primario in mieloma multiplo, linfoma a cellule mantellari e leucemia linfocitica cronica.
Adaptive Biotechnologies (Nasdaq: ADPT) anunció que su prueba clonoSEQ® para la evaluación de la enfermedad residual medible (MRD) se presentará en más de 65 resúmenes en la 66ª Reunión Anual de ASH. Las presentaciones abarcan ocho tipos diferentes de cáncer de sangre e incluyen una sesión plenaria, un resumen de última hora y 25 presentaciones orales. Los estudios demuestran el papel de clonoSEQ como un estándar para la medición de la eficacia en ensayos clínicos clave y destacan sus ventajas tanto en ensayos clínicos como en la práctica del mundo real. Varios estudios que cambian la práctica utilizan MRD como punto final primario en mieloma múltiple, linfoma de células del manto y leucemia linfocítica crónica.
Adaptive Biotechnologies (Nasdaq: ADPT)는 그들의 clonoSEQ® 테스트가 66회 ASH 연례 회의에서 65건 이상의 초록으로 발표될 것이라고 발표했습니다. 발표는 8가지 다양한 혈액암 유형을 포함하며, 기조 세션, 늦게 발표되는 초록, 25건의 구두 발표를 포함합니다. 연구는 clonoSEQ가 주요 임상 시험에서 효능 측정의 표준으로서의 역할을 입증하며, 임상 시험과 실제 실습 모두에서 그 장점을 강조합니다. 여러 개의 실용적인 변화 연구는 다발성 골수종, 뺨세포 림프종 및 만성 림프구 백혈병에서 MRD를 주요 최종점으로 사용합니다.
Adaptive Biotechnologies (Nasdaq: ADPT) a annoncé que son test clonoSEQ® pour l'évaluation de la maladie résiduelle mesurable (MRD) sera présenté dans plus de 65 résumés lors de la 66e Réunion Annuelle de l'ASH. Les présentations couvrent huit types différents de cancer du sang et comprennent une séance plénière, un résumé à fort impact et 25 présentations orales. Les études démontrent le rôle de clonoSEQ en tant que standard de mesure de l'efficacité dans des essais cliniques fondamentaux et mettent en avant ses avantages tant dans les essais cliniques que dans la pratique réelle. Plusieurs études qui changent la donne utilisent le MRD comme critère principal dans le myélome multiple, le lymphome à cellules du manteau et la leucémie lymphocytaire chronique.
Adaptive Biotechnologies (Nasdaq: ADPT) gab bekannt, dass ihr clonoSEQ®-Test zur Bewertung von messbarer Resterkrankung (MRD) in über 65 Abstracts auf dem 66. ASH-Jahrestreffen vorgestellt wird. Die Präsentationen decken acht verschiedene Arten von Blutkrebs ab und beinhalten eine Plenarsitzung, ein kurzfriste Abstract und 25 mündliche Präsentationen. Die Studien zeigen die Rolle von clonoSEQ als Standard für die Effektivitätsmessung in entscheidenden klinischen Studien und heben die Vorteile sowohl in klinischen Studien als auch in der realen Praxis hervor. Mehrere praxisverändernde Studien verwenden MRD als primären Endpunkt bei multiplem Myelom, Mantelzellenlymphom und chronischer lymphatischer Leukämie.
- Record-breaking number of studies (65+ abstracts) featuring clonoSEQ at ASH Annual Meeting
- Widespread adoption of clonoSEQ as standard for clinical trials and practice
- Product validation through practice-changing studies across multiple blood cancer types
- None.
Insights
The extensive presence of clonoSEQ in 65+ abstracts at ASH, including a plenary session and late-breaking abstract, demonstrates strong clinical validation and growing adoption in blood cancer diagnostics. The test's inclusion as a primary endpoint in pivotal trials for multiple myeloma, mantle cell lymphoma and CLL indicates its increasing importance in drug development and clinical decision-making.
The test's high sensitivity for measuring minimal residual disease (MRD) provides important data for treatment efficacy assessment. This expanded validation across eight blood cancer types strengthens clonoSEQ's market position and potential revenue growth. However, the immediate financial impact may be gradual as clinical adoption cycles typically lag behind research validation.
SEATTLE, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced that its next-generation sequencing (NGS)-based clonoSEQ® test for measurable residual disease (MRD) assessment will be included in more than 65 abstracts across eight different types of blood cancer at the 66th Annual Meeting of the American Society of Hematology (ASH) taking place December 7-10, 2024, in San Diego. Among these abstracts are a plenary session presentation, a late-breaking abstract and 25 other oral presentations.
“We are inspired to see clonoSEQ MRD testing featured in a record-breaking number of studies at this year’s ASH Annual Meeting,” said Susan Bobulsky, chief commercial officer, MRD, Adaptive Biotechnologies. “The increasingly widespread use of clonoSEQ as a highly sensitive test to support clinical decision-making and as a primary endpoint in clinical trials highlights its multi-faceted role in advancing precision medicine in hematology.”
Multiple studies underscore the use of clonoSEQ as the standard for demonstrating efficacy in pivotal clinical trials and highlight advantages of leveraging the highest sensitivity in both clinical trials and real-world practice across various blood cancers. Notably, several practice-changing studies using MRD as a primary endpoint in multiple myeloma (MM), mantle cell lymphoma (MCL), and chronic lymphocytic leukemia (CLL), as well as studies using MRD interventionally in acute lymphoblastic leukemia (ALL), MM, MCL, and CLL, further validate its critical role in assessing deep therapeutic responses and informing treatment decisions.
A complete list of the accepted abstracts featuring clonoSEQ is available here.
About clonoSEQ
clonoSEQ is the first and only FDA-cleared in vitro diagnostic (IVD) test to detect minimal residual disease (MRD) in bone marrow from patients with multiple myeloma (MM) or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). clonoSEQ testing for diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) patients is currently available for clinical use as a laboratory-developed test (LDT) performed at Adaptive's CLIA-certified lab in Seattle, WA. clonoSEQ is CE-marked under IVDR in the EU. For the approved intended use in the EU under IVDR, please refer to the instructions for use, available on request.
clonoSEQ leverages Adaptive Biotechnologies’ proprietary immune medicine platform to identify and quantify specific DNA sequences found in malignant cells, allowing clinicians to assess and monitor MRD during and after treatment. The test provides standardized, accurate, and sensitive measurement of MRD that allows physicians to predict patient outcomes, assess response to treatment, inform changes in therapy, monitor disease burden over time, and detect potential relapse early. Clinical practice guidelines in hematological malignancies recognize that MRD status is a reliable indicator of clinical outcomes and response to therapy, and clinical outcomes have been shown to be strongly associated with MRD levels measured by the clonoSEQ in patients diagnosed with CLL, MM, ALL and DLBCL.
For important information about the FDA-cleared uses of clonoSEQ, including the full intended use, limitations, and detailed performance characteristics, please visit www.clonoSEQ.com/technical-summary.
About Adaptive Biotechnologies
Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business areas: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer, autoimmune disorders, and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.
Forward Looking Statements
This press release contains forward-looking statements that are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.
In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.
ADAPTIVE INVESTORS
Karina Calzadilla, Vice President, Investor Relations
201-396-1687
investors@adaptivebiotech.com
ADAPTIVE MEDIA
Erica Jones, Associate Director, Corporate Communications
206-279-2423
media@adaptivebiotech.com
FAQ
How many abstracts featuring clonoSEQ will be presented at ASH 2024?
What types of presentations will feature ADPT's clonoSEQ at ASH 2024?
Which blood cancers are being studied with clonoSEQ in the ASH 2024 presentations?
